Medical Bulletin 29/May/2026 - Video

Here are the top medical news for today:

Researchers Explore How Daily Spices May Support Better Cardiovascular Health Naturally

A dash of cinnamon, a spoon of turmeric, a little garlic in dinner — those everyday flavor boosters may be doing far more than improving taste.

A new review published in Nutrition Reviews suggests that common culinary spices and herbs could help improve several markers linked to heart and metabolic health. Researchers analyzed findings from multiple controlled studies examining how regular spice consumption affects blood pressure, inflammation, blood sugar, cholesterol, and even gut bacteria in adults at increased cardiometabolic risk.

Cardiovascular disease remains the world’s leading cause of death, with unhealthy diets playing a major role. Scientists say spices such as cinnamon, turmeric, ginger, oregano, rosemary, garlic, and black pepper contain bioactive compounds that may reduce inflammation and oxidative stress, two processes closely tied to diabetes, obesity, and heart disease.

In one post-meal study, overweight adults consumed a high-fat meal containing a blend of spices including cinnamon, cloves, garlic powder, ginger, paprika, oregano, rosemary, and turmeric. Researchers found insulin levels dropped by 21% and triglycerides fell by 31% compared with the same meal without spices. Blood antioxidant activity also increased after the spiced meal.

Another experiment found that adding spices to meals improved blood vessel function and lowered inflammatory markers after eating. However, researchers noted that psychological stress weakened some of these benefits, suggesting stress itself can interfere with healthy metabolic responses.

The review also highlighted a four-week feeding trial involving adults at cardiometabolic risk. Participants consumed diets with low, moderate, or high amounts of herbs and spices. The heavily seasoned diet, providing about 6.6 grams of spices daily, significantly lowered 24-hour blood pressure readings compared with lower-spice diets.

Researchers also observed favorable changes in immune activity and gut bacteria. Higher spice intake increased beneficial microbial groups linked to short-chain fatty acid production, compounds associated with gut and metabolic health.

REFERENCE: Kris-Etherton, P. M., Rogers, C. J., Oh, E. S., West, S. G., Sandhu, A. K., Burton-Freeman, B., Huang, Y., Proctor, D. N., & Petersen, K. S. (2026). Cardiometabolic and microbiome effects of spices and herbs. Nutrition Reviews. 84(Supplement_1). 70–75. DOI: 10.1093/nutrit/nuaf267 https://academic.oup.com/nutritionreviews/article/84/Supplement_1/70/8692889

Scientists Develop Promising New Drug to Combat Severe Fatty Liver Disease

A new experimental drug may have found a way to strike fatty liver disease at its source instead of simply treating the fallout.

Researchers at the University of California San Diego School of Medicine reported that a drug called ION224 significantly improved liver health in people with metabolic dysfunction-associated steatohepatitis (MASH), a dangerous form of fatty liver disease closely linked to obesity and type 2 diabetes. The findings, published in The Lancet, are raising hopes for a more targeted treatment approach against a disease that can silently progress to cirrhosis, liver failure, or liver cancer.

MASH, previously known as NASH, develops when excess fat builds up inside liver cells, triggering inflammation and scarring over time. Current treatments mainly focus on weight loss and lifestyle changes, but ION224 works differently. The drug blocks an enzyme called DGAT2, which plays a key role in producing and storing fat inside the liver.

The Phase IIb clinical trial involved 160 adults in the United States with MASH and mild to moderate liver fibrosis. Participants received monthly injections of ION224 or a placebo over 51 weeks.

The results were encouraging. Around 60% of patients receiving the highest dose showed meaningful improvements in liver inflammation and fibrosis compared with placebo recipients. Researchers also reported that the treatment was generally well tolerated, with no major safety concerns linked to the drug.

Scientists say the findings are especially important because ION224 appeared to improve liver disease even without major weight loss. That means it could potentially work alongside popular GLP-1 weight-loss medications in future combination therapies.

Researchers caution that larger Phase III trials are still needed before the drug could become widely available. But experts say the study marks one of the strongest signs yet that directly targeting liver fat production may help slow or even reverse the progression of MASH.

REFERENCE: Rohit Loomba, Erin Morgan, Keyvan Yousefi, Dan Li, Richard Geary, Sanjay Bhanot, Naim Alkhouri. Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 2025; 406 (10505): 821 DOI: 10.1016/S0140-6736(25)00979-1

Scientists Develop Enhanced Vitamin K Compound That May Help Repair Brain Damage

A vitamin long associated with blood clotting and bone health may now be opening an unexpected door in brain repair research.

Scientists in Japan have developed enhanced vitamin K compounds that helped immature brain cells transform into neurons far more effectively than natural vitamin K. The findings, published in ACS Chemical Neuroscience, are raising hopes for future treatments aimed at diseases such as Alzheimer's, Parkinson's, and Huntington's, where progressive neuron loss drives memory decline, movement problems, and cognitive impairment.

Researchers from the Shibaura Institute of Technology created a series of modified vitamin K molecules designed to strengthen the vitamin’s activity inside the nervous system. One experimental compound stood out, showing roughly three times greater ability to trigger neuronal differentiation compared with natural vitamin K forms.

The scientists combined vitamin K structures with retinoic acid, a vitamin A derivative already known to support nerve cell development. In laboratory experiments using mouse neural progenitor cells, the hybrid compounds activated pathways involved in neuronal growth and maturation.

One major discovery involved a receptor called mGluR1, which helps regulate communication between neurons. The new vitamin K compound appeared to interact strongly with this receptor, potentially helping drive the transformation of immature cells into functioning neurons.

The team also found that the compound successfully crossed the blood-brain barrier in mice and produced higher concentrations in the brain than natural vitamin K alone. That is considered a key challenge in developing treatments for neurological disease.

Researchers stress that the findings are still early and limited to cell and animal studies. No human trials have yet shown that vitamin K based compounds can reverse neurodegenerative disease.

Still, experts say the work represents an important shift toward regenerative approaches that aim not just to slow disease progression, but to help rebuild damaged brain tissue.

Current Alzheimer's drugs can modestly slow decline in some patients, but they do not restore lost neurons or recover damaged brain function. Scientists hope future regenerative therapies may eventually target that missing piece.

REFERENCE: Yoshihisa Hirota, Taiki Sato, Rina Watanabe, Kazuki Takeda, Sho Sano, Satoshi Asano, Yuki Shibahashi, Yumi Yasuda, Yuta Takagi, Yutaro Yamashita, Wu YuXin, Mikino Arakawa, Yuri Maitani, Vannessa Lawai, Kurumi Nakagawa, Natsuko Furukawa, Atsuko Takeuchi, Chisato Tode, Maya Kamao, Akimori Wada, Zainab Ngaini, Yoshitomo Suhara. A New Class of Vitamin K Analogues Containing the Side Chain of Retinoic Acid Have Enhanced Activity for Inducing Neuronal Differentiation. ACS Chemical Neuroscience, 2025; 16 (15): 2812 DOI: 10.1021/acschemneuro.5c00111